Description
Sorafenib (marketed as Nexavar by Bayer) is a multikinase inhibitor targeting a number of serine/threonine and receptor tyrosine kinases. It is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primar.
Abbr
Sorafenib(ZHX2, KDR)
Product Overview
multikinase inhibitor targeting a number of serine/threonine and receptor tyrosine kinases
Stability
2 years -20 centigrade Powder
1 month -4 centigrade in DMSO
More than one month -80 centigrade in DMSO
Molecular Formula
C21H16ClF3N4O3
Chemical Name
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
Solubility
DMSO > 112mg/mL Water >1mg/mL Ethanol > 4mg/mL